<code id='5C88A888E4'></code><style id='5C88A888E4'></style>
    • <acronym id='5C88A888E4'></acronym>
      <center id='5C88A888E4'><center id='5C88A888E4'><tfoot id='5C88A888E4'></tfoot></center><abbr id='5C88A888E4'><dir id='5C88A888E4'><tfoot id='5C88A888E4'></tfoot><noframes id='5C88A888E4'>

    • <optgroup id='5C88A888E4'><strike id='5C88A888E4'><sup id='5C88A888E4'></sup></strike><code id='5C88A888E4'></code></optgroup>
        1. <b id='5C88A888E4'><label id='5C88A888E4'><select id='5C88A888E4'><dt id='5C88A888E4'><span id='5C88A888E4'></span></dt></select></label></b><u id='5C88A888E4'></u>
          <i id='5C88A888E4'><strike id='5C88A888E4'><tt id='5C88A888E4'><pre id='5C88A888E4'></pre></tt></strike></i>

          Home / knowledge / explore

          explore


          explore

          author:hotspot    Page View:7
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In